INTRODUCTION
Burkitt's lymphoma patients carry a chromosomal translocation involving a breakpoint in chromosome 8 which was shown to harbor a gene with similarity to the v-Myc myelocytomatosis viral oncogene and therefore was named c-Myc, for cellular form of Myc [1] [2] [3] [4] . This translocation caused overexpression of c-Myc, leading to the disease. Cancer cells are frequently dependent on oncogenes like c-Myc for growth and survival, a process that has been named oncogene addiction 5 . c-Myc is the most frequently overexpressed oncogene in tumours, including breast cancer, colon cancer and lung cancer 6 . The c-Myc protein is a basic Helix-Loop-Helix style transcription factor, driving the expression of a very extensive set of genes via E-boxes for Enhancer box sequences in promoter regions of these genes 7 . c-Myc drives cell cycle progression, particularly through a key role in S-phase to control replication 8 . Small ubiquitin-like modifiers (SUMOs) are ubiquitin family members that are conjugated to extensive sets of target proteins as post-translational modifications [9] [10] [11] . The SUMO conjugation cascade consists of the SUMO E1 heterodimer SAE1/2, the unique SUMO E2 UBC9 and a restricted set of SUMO E3 ligases, comprising PIAS family members. SUMOylation is a reversible process. At least six SUMO proteases deSUMOylate target proteins and participate in the maturation of SUMO precursor proteins 12 . SUMOylation predominantly regulates nuclear processes. Pharmacological inhibition of c-Myc is notoriously challenging and inhibitors of c-Myc are still not available, despite three decades of c-Myc research. To explore indirect manners to block c-Myc, a search for non-oncogene addiction (NOA) of c-Myc-driven tumourigenesis was recently performed to identify cellular pathways cooperating with upregulated c-Myc 13 . In a genome-wide shRNA screen, it was found that c-Myc-driven proliferation is strongly dependent on the SUMOylation pathway. Upon knockdown of the SUMO E1 or E2 components, c-Myc-dependent proliferation was strongly inhibited. However, the relevant SUMOylated proteins in this process remained to be identified. Here, we provide evidence that c-Myc is a direct target for SUMOylation. The SUMOylated form of c-Myc is stabilized by proteasome inhibitors, indicating that SUMOylated c-Myc is subsequently ubiquitylated and degraded by the proteasome.
RESULTS

c-Myc is a target for SUMOylation
Previously, it was shown that c-Myc-driven tumours are strongly dependent on SUMOylation 13 . Searching for relevant SUMO target proteins in this context, we tested whether c-Myc is a target for SUMOylation. A subsection of SUMOylated proteins is ubiquitylated and degraded by the proteasome 14 , therefore we included the proteasome inhibitors MG132 and epoxomicin in these experiments. U2OS cells stably expressing low levels of His-tagged SUMO2 were treated with one of the proteasome inhibitors or DMSO as a control. Subsequently, cells were lysed in a denaturing buffer and SUMO2 conjugates were enriched using immobilized metal affinity chromatography (IMAC). SUMO-enriched fractions and input samples were analyzed by immunoblotting. Using this approach, we were able to detect a considerable amount of SUMOylated endogenous c-Myc, indicating that c-Myc is a target for SUMOylation ( Figure 1 ).
In figure 1 , the SUMOylated forms of c-Myc are visible in the 65 kDa -200 kDa range, an exceptionally large region for SUMOylation, suggesting that c-Myc might be conjugated to SUMO polymers. To investigate the potential conjugation of c-Myc to SUMO polymers, we compared the conjugation of c-Myc to wildtype SUMO2 (WT) with that to a lysine-deficient mutant of SUMO2 (K0) expressed at low levels in U2OS cells. Purified SUMO conjugates from both cell lines were analyzed by immunoblotting for c-Myc SUMOylation (Figure 2A ), Figure 1 . SUMOylation of endogenous c-Myc in a proteasome inhibitor-dependent manner. U2OS cells stably expressing His-tagged SUMO2 were treated for 6 hours with DMSO or a proteasome inhibitor, either MG132 or epoxomicin. The parental U2OS cell line was included as a negative control for the enrichment of His-SUMO2 conjugates. Input and pulldown samples were separated by SDS-PAGE, transferred onto a membrane and incubated with antibodies to detect c-Myc, SUMO2/3 and the His-tag. In addition, the membrane was stained with Ponceau S as a loading control. The asterisks represents an a-specific band. K0  WT  -K0  WT  -K0  WT  -His-SUMO2: His-SUMO2 but no clear differences in SUMOylation levels could be observed, indicating that SUMO polymers play a limited role. However, we cannot fully rule out a role for SUMO polymers, since the observed pattern of c-Myc conjugated to wildtype SUMO2 differs slightly from the pattern of c-Myc conjugated to the lysine-deficient SUMO2 mutant.
To determine whether c-Myc is co-modified by SUMO and ubiquitin 14 , we developed a double purification method to enrich for SUMO2 and ubiquitin ( Figure 2B ). U2OS cells stably expressing His-SUMO2 and Flag-ubiquitin at low levels were established, and SUMO2 and ubiquitin conjugates were consecutively enriched and analyzed by immunoblotting ( Figure 2C ). Additionally, a similar strategy was used to first enrich ubiquitin and then SUMO2 conjugates from U2OS cells stably expressing low levels of His-ubiquitin and Flag-SUMO2 ( Figure S1 ). The results indicate that high molecular weight c-Myc forms were indeed co-modified by both small protein modifiers as expected, although the amount of co-modified c-Myc appeared to be limited compared to the amount of SUMOylated or ubiquitylated c-Myc.
Additionally, these data were confirmed by performing an in vitro deSUMOylation and/ or deubiquitylation assay. His conjugates were purified from U2OS cells expressing either His-SUMO2 or His-ubiquitin and subsequently incubated with the catalytic domain (CD) of SENP2 or/and USP2 ( Figure 2D ). These results confirmed that a fraction of SUMOylated c-Myc was also ubiquitylated and vice versa.
A limited role for the SUMO-targeted ubiquitin ligase RNF4 Experiments described in the previous section indicated that c-Myc is co-modified by SUMO and ubiquitin to a limited extent. SUMO-targeted ubiquitin ligases (STUbLs) are responsible for ubiquitylating SUMOylated proteins 15 . To study whether the STUbL RNF4 [16] [17] [18] [19] is responsible for ubiquitylating SUMOylated c-Myc, we performed RNF4 knockdown experiments ( Figure 3A) . Knocking down RNF4 resulted in a clear increase in SUMOylated c-Myc, indicating involvement of this STUbL in the co-modification of c-Myc. SUMOylated c-Myc could not be detected upon RNF4 knockdown in the absence of proteasome inhibitors, indicating that RNF4 plays a limited role in c-Myc regulation. One explanation for these findings could be the involvement of another STUbL. The second known human STUbL is RNF111, also known as Arkadia, a component of the DNA damage response [20] [21] [22] . Similar knockdown experiments were performed as described above ( Figure 3B ), but no changes in c-Myc SUMOylation could be observed, ruling out a role for RNF111. As our results suggest that RNF4 ubiquitylates SUMOylated c-Myc, knocking down RNF4 should decrease the ubiquitylated fraction of SUMOylated c-Myc. To address this point, we purified His-SUMO2 conjugates after RNF4 knockdown, in vitro deSUMOylated and deubiquitylated the conjugates and performed immunoblotting to verify c-Myc modification ( Figure 3C ). In agreement with our hypothesis, knocking down RNF4 resulted in a reduction of the ubiquitylated fraction of SUMOylated c-Myc. We conclude that RNF4 plays a limited role in regulating SUMOylated c-Myc. shRNA:
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Figure 3. SUMO-targeted ubiquitin ligases. U2OS cells stably expressing His-SUMO2 were infected with lentiviruses encoding control, RNF4 (A) or RNF111 (B) shRNAs. Upon knockdown, cells were treated or not with MG132 for 6 hours. A pulldown was performed, followed by SDS-PAGE and immunoblotting using antibodies against c-Myc and SUMO2/3. Anti-RNF4 and anti-RNF111 antibodies were used to check knockdown efficiency. Ponceau S staining was performed as a loading control. The asterisk indicates an a-specific band. (C) U2OS cells stably expressing His-SUMO2 were infected with lentiviruses encoding control or RNF4 shRNAs. Upon knockdown, cells were treated or not with MG132 for 6 hours. A pulldown was performed and samples were in vitro deSUMOylated and/or deubiquitylated, followed by SDS-PAGE and immunoblotting using antibodies against c-Myc and SUMO2/3. RNF4 shRNA-mediated knockdown efficiency is shown. The line indicates the ubiquitylated c-Myc on the SUMOylated c-Myc fraction.
PIAS1 and SENP7 regulate reversible SUMOylation of c-Myc
SUMO conjugation to target proteins is regulated by E3 ligases, including PIAS family members. These E3 ligases contain a so-called SP-RING domain, which stands for RING domain identified in Siz and PIAS proteins, with the Siz proteins found in yeast and the PIAS proteins found in mammalian cells 23 . Similar to ubiquitin RING E3 ligases, the structure of the SP-RING domain is coordinated by Zinc binding 24 . In order to identify a c-Myc SUMO ligase, we transfected U2OS cells expressing His-SUMO2 with plasmids to overexpress the different PIAS family members ( Figure S2 ). Only overexpression of PIAS1 resulted in an increase in SUMOylated c-Myc level. Therefore, we tested knockdown constructs against PIAS1. U2OS cells expressing His-SUMO2 were infected with a lentiviral construct encoding a short hairpin targeting PIAS1. PIAS1 knockdown resulted in a striking reduction of SUMOylated c-Myc, indicating that PIAS1, a major SUMO E3 ligase responsible for the conjugation of many different SUMO substrates, is also responsible for SUMOylating c-Myc ( Figure 4A ). Covalent SUMOylation is a dynamic and reversible process. SENP family members are proteases that remove SUMOs from substrates 12 . In order to identify a SENP family member responsible for deconjugating c-Myc, we tested different knockdown constructs. Knockdown of SENP7 resulted in an increase in c-Myc SUMOylation, indicating that SENP7 is responsible for removing SUMOs from c-Myc ( Figure 4B ). Subsequently, we tested whether PIAS1 and SENP7 affected c-Myc transcriptional activity, using a c-Myc-driven luciferase reporter. Knocking down PIAS1 enhanced c-Myc-driven transcription about four-fold ( Figure 4C ). This result indicates that SUMOylation counteracts c-Myc activity, consistent with the frequently observed repression of transcription factors by SUMOylation 25 . Knocking down PIAS1 virtually abolished c-Myc SUMOylation, indicating a direct effect of PIAS1 on c-Myc SUMOylation, although indirect effects cannot be excluded.
SUMOylation and phosphorylation of c-Myc
c-Myc is extensively controlled via post-translational modifications, with a major role for phosphorylation. Two key phosphorylated residues in c-Myc, associated with the stability of the protein, are Thr-58 and Ser-62 26, 27 . Phosphorylation of Ser-62 is linked to the Ras-ERK pathway and phosphorylation of Thr-58 is carried out by GSK3. Ser-62 phosphorylation of c-Myc leads to subsequent phosphorylation of Thr-58 and degradation via the ubiquitinproteasome pathway 27 . To study whether phosphorylation plays a role in c-Myc SUMOylation via phosphorylationdependent SUMO modification 28 , we tested whether SUMOylated c-Myc is phosphorylated on Ser-62 and Thr-58 using a phosphorylation-specific antibody. In our first attempt, we failed to detect phosphorylated c-Myc in a SUMO-purified fraction, but we noted that the amount of phosphorylated c-Myc that could be detected by the antibody was limited already at total protein level ( Figure 5A ). To increase the signal, we repeated the experiment, this time cleaving SUMO conjugates after purification using the recombinant catalytic domain of SENP2 ( Figure 5B ). Using this approach, we visualized the phosphorylated form of c-Myc after SUMO purification, indicating that a fraction of SUMO-conjugated c-Myc is also phosphorylated. Furthermore, the negative results obtained in figure 5A could potentially be explained by blocking of the epitope for the phosphorylation-specific c-Myc antibody as a result of SUMOylation, or alternatively, the sensitivity of the antibody could be the critical factor. Anti-c-Myc
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Figure 4. PIAS1 and SENP7 mediate the reversible SUMOylation of c-Myc. (A) U2OS cells stably expressing
His-SUMO2 were infected with lentiviruses encoding control or PIAS1 shRNAs. Upon knockdown, cells were treated with MG132 and a pulldown was performed. Samples were analyzed by SDS-PAGE and immunoblotting using antibodies against c-Myc and SUMO2/3. Anti-PIAS1 antibody was used to check knockdown efficiency. Ponceau S staining was used as a loading control. (B) U2OS cells stably expressing His-SUMO2 were infected with lentiviruses encoding control or SENP7 shRNAs. Upon knockdown, cells were treated with MG132 and a pulldown was performed. Samples were analyzed by SDS-PAGE and immunoblotting using antibodies against c-Myc and SUMO2/3. Anti-SENP7 antibody was used to check knockdown efficiency. Ponceau S staining was used as loading control. (C) A luciferase assay was performed to check c-Myc activity upon PIAS1 or SENP7 knockdown. The average and SEM of six different replicates are shown. The difference between control and PIAS1 knockdown is significant (p<0.01), indicated by the asterisk. conjugates. Three days after transfection these cells were treated for 6 hours with the proteasome inhibitor MG132, lysed and a His-SUMO2 pulldown was performed. Input and pulldown samples were separated by SDS-PAGE, transferred onto a membrane and incubated with antibodies to detect the HA-tag and the His-tag.
(D) U2OS cells stably expressing His-SUMO2 and Flag-ubiquitin were transfected with a control plasmid, HAtagged c-Myc wildtype or HA-tagged c-Myc T58A/S62A. Three days after transfection these cells were treated for 6 hours with MG132, lysed and a His-SUMO2 plus Flag-ubiquitin purification was performed. Input, His pulldown and His pulldown plus Flag-IP samples were separated by SDS-PAGE, transferred onto a membrane and incubated with antibodies to detect phosphorylated c-Myc, the HA-tag, the His-tag and the Flag-tag.
To determine whether phosphorylation is required for c-Myc SUMOylation, we generated a c-Myc phosphorylation mutant where Thr-58 and Ser-62 were mutated into Ala. U2OS cells were transiently transfected with a control plasmid, HA-tagged c-Myc wildtype or HA-tagged c-Myc T58A/S62A mutant. Subsequently, these cells were treated with the proteasome inhibitor MG132, SUMO conjugates were enriched and analyzed by immunoblotting ( Figure 5C ). In agreement with the signaling cascade described above, the c-Myc T58A/S62A mutant was more stable in input samples due to decreased degradation via the ubiquitin-proteasome pathway. Consequently, the SUMOylation level of c-Myc T58A/S62A was modestly increased compared to the SUMOylation level of c-Myc wildtype, corresponding to the increase observed for total levels of c-Myc T58A/S62A. However, no additional changes in SUMOylation level of c-Myc T58A/S62A were observed, indicating that phosphorylation is not required for c-Myc SUMOylation.
Since it is known that phosphorylation at Thr-58 and Ser-62 stimulates c-Myc degradation via the ubiquitin-proteasome system, we studied whether mutating these phosphorylation sites affected the ubiquitylation of SUMOylated c-Myc. U2OS cells stably expressing His-SUMO2 and Flag-ubiquitin at low levels were transiently transfected with a control plasmid, HA-tagged c-Myc wildtype or HA-tagged c-Myc T58A/S62A. Subsequently, SUMO2 and ubiquitin conjugates were consecutively enriched and analyzed by immunoblotting ( Figure 5D ). However, no changes in co-modification level by SUMO and ubiquitin were observed between the c-Myc wildtype and c-Myc T58A/S62A mutant. These data indicate that phosphorylation at Thr-58 and Ser-62 does not affect the ubiquitylation levels of SUMOylated c-Myc. In addition, we investigated whether SUMOylation of c-Myc influences its phosphorylation by knocking down PIAS1 ( Figure 5A ), based on our finding that PIAS1 is responsible for c-Myc SUMOylation ( Figure 4A ). Immunoblotting analysis revealed no change in c-Myc phosphorylation on Thr-58 and Ser-62 upon PIAS1 knockdown. Combined, our data indicate that although doubly modified c-Myc can be detected, no functional crosstalk between SUMOylation and phosphorylation of c-Myc could be established.
Mapping SUMO acceptor lysines in c-Myc
During the next phase of the project, we investigated the SUMO acceptor lysines in c-Myc. SUMOs are frequently conjugated to acceptor lysines in target proteins situated in the SUMOylation consensus motif YKxE 32 . Surprisingly, c-Myc lacks lysines situated in this SUMOylation consensus motif. To identify SUMO acceptor lysines, we employed a mass spectrometry approach, similar to the approach described in our previous project 32 . HeLa cells stably expressing His-SUMO2 were treated with MG132, lysed and SUMO conjugates were subsequently purified by IMAC, digested by LysC and repurified as described before 32 . Site-mapping was enabled by a Q87R mutation in SUMO, mimicking yeast SUMO Smt3. In total, we identified ten SUMO acceptor sites in c-Myc, including lysines 52, 148, 157, 317, 323, 326, 389, 392, 398 and 430 ( Figure 6A ). HeLa cells were particularly useful for these experiments since SUMOylation levels in this cell line are considerably higher compared to SUMOylation levels in U2OS cells. Subsequently, a c-Myc mutant was generated using a synthetic approach to replace SUMO acceptor lysines by arginines (10KR). U2OS cells were infected with lentiviruses encoding GFP and either Flag-tagged c-Myc wildtype or 10KR mutant. Cells were sorted by flow cytometry to obtain cells stably expressing low levels of the transgene ( Figure 6B ). Subsequently, these cells were transduced with His-tagged SUMO2 and puromycin selected. To determine the effect of mutating the ten SUMO acceptor lysines in c-Myc on its SUMOylation level, these cells were treated with the proteasome inhibitor MG132 or DMSO as a control. Upon cell lysis, SUMO conjugates were enriched and analyzed by immunoblotting ( Figure 6C ). Despite all these mutations, c-Myc 10KR was still efficiently conjugated to SUMO. This might indicate that SUMOylation in the ubiquitin-proteasome pathway acts promiscuously, analogous to ubiquitylation.
DISCUSSION
We have uncovered a role for SUMOylation in the regulation of c-Myc. SUMOylated c-Myc was purified and identified from U2OS cells and HeLa cells treated with the proteasome inhibitors MG132 or epoxomicin, indicating that SUMOylated c-Myc is rapidly degraded by the proteasome. Ten SUMO acceptor lysines were mapped by mass spectrometry, but mutating these ten sites did not result in a loss of SUMOylation. Conjugation of SUMO to c-Myc could be blocked by PIAS1 knockdown, indicating that PIAS1 is the SUMO E3 ligase responsible for the SUMOylation of c-Myc. Knocking down PIAS1 enhanced c-Myc transcriptional activity four-fold, consistent with a role for SUMOylation in transcriptional repression of c-Myc (Figure 7) . Deconjugation of SUMO could be reduced by SENP7 knockdown, revealing the SUMO protease responsible for deSUMOylation of c-Myc. Together, these results provide novel insight into the complexity of c-Myc post-translational regulation. Previously, it was found that the c-Myc oncogenic program is dependent on a properly functioning SUMOylation system 13 . Combined with our results, this could indicate that SUMOylation is needed to counteract excessive c-Myc activity by providing cells with a system to limit the activity of overexpressed c-Myc. When the SUMOylation system is defective, changes in the c-Myc transcriptional program caused mitotic catastrophy as observed by Kessler et al (2012) . Nevertheless, it is somewhat surprising to note that Kessler et al found that inactivation of the SUMO E1 subunit SAE2 switched a transcriptional subprogram of c-Myc from activated to repressed, whereas based on our data one would expect a transcriptional subprogram of c-Myc to be switched from repressed to activated upon impairing SUMOylation. Given the complexity of SUMOylation, targeting hundreds of substrates 11, 14, 31, 33, 34 , it is likely that the observations of Kessler et al result from SUMO group modification of many different target proteins 35 . Similarly, PIAS1 knockdown affects a broad range of SUMO target proteins in addition to c-Myc.
The promiscuous behavior of SUMO towards c-Myc acceptor lysines is rarely noted in the SUMO field so far. SUMOylation is frequently targeted to lysines situated in SUMOylation consensus motifs [9] [10] [11] 31 . By mutating these SUMO acceptor lysines, many different SUMOylation-impaired mutants have been generated. Promiscuous behavior towards acceptor lysines in target proteins is a well-known phenomenon in the ubiquitin field. Weissman and coworkers demonstrated that ubiquitin has little specificity for lysine residues in T cell receptors 36 . Even lysines introduced into the protein at aberrant positions acted as ubiquitin acceptor sites. Multiple lysines in cyclin B act as acceptor sites for ubiquitin and no single lysine residue is essential for cyclin B degradation, demonstrating the redundant nature of ubiquitin acceptor lysines in cyclin B 37 . In a large scale ubiquitin proteomics study, site promiscuity was deduced from a low level of conservation of ubiquitin acceptor lysines 38 . In contrast, mono-ubiquitylation acts in a more site-specific manner 39 . Our data would be consistent with site promiscuity of SUMO for proteins that are subsequently ubiquitylated and degraded, if our results can be generalized. We anticipate that site promiscuity is less likely to occur when classical KxE-type SUMOylation consensus motifs are involved.
SENP7 is a SUMO protease with a preference for deconjugating SUMO2 and SUMO3, particularly in a polymeric form 12, [40] [41] [42] . Precursor SUMO1, SUMO2 and SUMO3 and SUMO1 polymers are poorly processed by SENP7 40, 41 . The catalytic domain of SENP7 consists of two separate parts interrupted by a stretch of amino acids 12, 43 . This feature is thought to contribute to its specificity for SUMO chains 44 . We found that SENP7 counteracted c-Myc SUMOylation ( Figure 4B ). Additionally, little difference was found between the conjugation of c-Myc to wildtype SUMO2 and to a lysine-deficient SUMO2 mutant (Figure 2A ), indicating that SUMO polymers play a limited role in the regulation of c-Myc. Three sets of SUMO acceptor lysines in c-Myc are closely spaced, including lysines 148-157, lysines 317-323-326 and lysines 389-392-398. We hypothesize that these closely spaced SUMOs on c-Myc might be important for the regulation of SUMOylated c-Myc by SENP7 (Figure 7 ). RNF4 is a known regulator of SUMO polymers, enabled by tightly spaced SUMO-interaction motifs 16, 42, 45, 46 . Analogous to SENP7, closely spaced SUMOylation events on c-Myc might provide an alternative binding site for RNF4 (Figure 7) . Nevertheless, we cannot fully exclude the presence of SUMO polymers, due to the presence of endogenous SUMO2/3 that can still form polymers together with exogenous SUMO2. Knocking down RNF4 was not sufficient to detect SUMOylated c-Myc in the absence of proteasome inhibition, indicating that other STUbLs could be involved in the regulation of c-Myc. Since our data did not support a role for RNF111, this could indicate that other STUbLs exist that remain to be identified. While our work was in progress, a study on the regulation of Myc family members by SUMOylation was published by Amati et al 47 . They showed that N-Myc and c-Myc are regulated by SUMOylation with the main focus of their work on N-Myc. They identified K349 in N-Myc as a dominant SUMO acceptor lysine, since mutating this lysine residue reduced N-Myc SUMOylation. However, no difference between N-Myc wildtype and the K349R mutant could be found in functional experiments. Lysine 326 in c-Myc was similarly replaced for an arginine, but this mutation did not reduce SUMOylation of the protein significantly. This is in agreement with our results, which show that c-Myc is conjugated to SUMO via at least ten different SUMO acceptor lysines and that c-Myc SUMOylation is a promiscuous process concerning SUMO acceptor lysines.
In conclusion, SUMOylation adds another level of complexity to the post-translational regulation of c-Myc. Intriguingly, linking c-Myc and SUMOylation might provide novel treatment options for c-Myc-driven tumours 13 . Since these tumours are dependent on the SUMOylation system, they are expected to be sensitive to disrupting SUMOylation. Pharmaceutical companies are increasingly interested in disrupting ubiquitin-like signaling 48, 49 , most notably in the case of Neddylation where the NEDD8 E1 inhibitor MLN4924 is currently being tested in the clinic 50, 51 . Analogously, SUMOylation inhibitors might become useful in the future to treat c-Myc-driven tumours.
MATERIAL AND METHODS
Cell lines and cell culture
Human osteosarcoma (U2OS) cells were cultured at 5% CO 2 and 37°C in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) and 100 U/ml penicillin plus 100 µg/ml streptomycin (Gibco). Stable cell lines were made by infecting U2OS cells with lentivirus containing the desired cDNA at an MOI of 3. Infected cells were either GFP sorted or puromycin (Calbiochem) selected to obtain low and equal expression levels.
Plasmids, mutagenesis and transfection
The HA-tagged c-Myc plasmid was a kind gift from Prof. R. Bernards (Netherlands Cancer Institute, Amsterdam, The Netherlands). HA-tagged c-Myc 10KR (Genscript) was used to replace the c-Myc wildtype cDNA in this construct, employing restriction enzymes KpnI and BamHI. Subsequently, c-Myc wildtype as well as c-Myc 10KR were cloned in between the PstI and XhoI sites of the plasmid pLV-CMV-IRES-eGFP 52 for lentiviral infection to obtain c-Myc encoding virus. The Flag-tag was introduced by PCR. In addition, a phosphorylationdeficient mutant of HA-tagged c-Myc was created by QuickChange site-directed mutagenesis (Stratagene) using oligonucleotides 5'-GAAATTCGAGCTGCTGCCCGCCCC GCCCCTGGCCCCTAGCCGCCGCTCCG-3' and 5'-CGGAGCGGCGGCTAGGGGCCAGGGG CGGGGCGGGCAGCAGCTCGAATTTC-3' to mutate both threonine 58 and serine 62 into alanines. U2OS cells were transfected using 2.5 µl polyethylenimine (PEI, 1 mg/ml; Alfa Aesar) per µg DNA. Plasmids for lentivirus mediated knockdown were obtained from the Mission® Library (Sigma-Aldrich) for RNF4 (TRCN0000017054), RNF111 (TRCN0000004207, TRCN0000004210), PIAS1 (TRCN0000004145) and SENP7 (TRCN0000004544, TRCN0000004547). SHC2 plasmid was used as a control. Tagged SUMO2 and ubiquitin constructs have been described before 31, 32 . PIAS expression constructs have also been described in before 53 .
Proteasome inhibition
To inhibit the proteasome, U2OS cells were treated for 6 hours with 10 µM MG132 (Sigma) or 5 µM epoxomicin (Sigma). DMSO was used to dissolve both inhibitors and, therefore, added for 6 hours to cells as a negative control.
His-SUMO2 purification
His-tagged SUMO2 conjugates were purified from U2OS cells as described before 31 . Briefly, U2OS cells stably expressing His-SUMO2 were washed and collected in PBS. Input samples were taken and the cells were lysed in guanidinium lysis buffer. After sonication, the lysates were equalized using BCA Protein Assay Reagent (Thermo Scientific). Subsequently, the His-SUMO2 conjugates were enriched using nickel-nitrilotriacetic acid beads (Qiagen). Upon multiple washing steps, the His-SUMO2 conjugates were eluted from the beads and separated by SDS-PAGE.
SUMO-ubiquitin double purification
Co-modified proteins by SUMO2 and ubiquitin were purified using a double purification method. U2OS cells stable expressing either His-SUMO2 and Flag-ubiquitin or His-ubiquitin and Flag-SUMO2 were treated with DMSO or MG132 as described above. Input samples were taken and cells were lysed according to the His-tag pulldown protocol. After enrichment for His-tagged conjugates, a part of the samples was kept separately. Dilution buffer (0.01 M Tris pH 7.0, 0.05 M Na 2 HPO 4 /NaH 2 PO 4 , 0.1 M NaCl and 0.07 M chloroacetamide) was added to the remaining sample, before it was centrifuged for 45 minutes at 13200 rpm at 4°C. Flag-M2 beads (Sigma) were added to the supernatant and incubated at 4°C. Subsequently, the samples were washed using wash buffer 1 (0.05 M Tris pH 7.5, 0.15 M NaCl and 0.07 M Chloroacetamide) and wash buffer 2 (0.05 M Tris pH 7.5 and 0.15 M NaCl). Co-modified proteins were eluted from the beads in 1x NuPAGE LDS sample buffer (Invitrogen) and separated by SDS-PAGE.
Electrophoresis and immunoblotting
Samples were either separated on 10% SDS-PAGE gels using Tris-Glycine buffer or on Novex 4-12% Bis-Tris gradient gels (Invitrogen) using MOPS buffer. Subsequently, separated proteins were transferred onto a Hybond-C extra membrane (Amersham, BioSciences). Total protein levels were visualized by staining the membrane with Ponceau S (Sigma). After washing in PBS containing 0.05% Tween (PBS/T, MERCK), membranes were blocked in PBS/T containing 8% milk. Membranes were incubated with primary antibodies overnight, including rabbit anti-c-Myc (ab32072; Abcam), mouse antipolyHistidine Clone HIS-1 (H1029; Sigma-Aldrich), mouse anti-SUMO2/3 (ab81375; Abcam), mouse monoclonal anti-Flag M2 (F3165; Sigma), rabbit anti-RNF4 54 , mouse anti-RNF111 (H00054778-M05; Abnova), rabbit anti-PIAS1 (GTX62050; Genetex), rabbit anti-SENP7 (A302-995A-1; Bethyl), rabbit anti-phospho c-Myc (ab32029; Abcam), mouse anti-ubiquitin (SC-8017, Santa-Cruz Biotechnology) and mouse monoclonal anti-HA.11 (MMS-101R; Covance). After washing membranes with PBS/T, they were incubated with secondary antibody, either donkey anti-rabbit or goat anti-mouse coupled to HRP (Thermo Scientific). After extensive washing with PBS/T, Pierce ECL 2 western blotting solution (Thermo Scientific) or Amersham ECL Prime (GE Healthcare) were used to visualize signals on FUJI medical X-ray films (FUJIFILM).
shRNA-mediated knockdown
Two million U2OS cells were plated in 15 cm dishes and incubated overnight. Subsequently, cells were infected with either the Mission® Library control shRNA (SHC2) or shRNAs directed against the indicated targets at an MOI of 2. The following day, medium was replaced for fresh medium. Three days post infection, cells were treated or not with MG132 and harvested for His-SUMO2 pulldown. In the case of RNF4 knockdown, cells were treated and harvested five days post infection.
Luciferase activity assay
In order to study endogenous c-Myc activity, a luciferase assay was employed. 150000 cells were plated per well in 6-well plates. The following day, cells were transfected in triplicate using 2.5 µl PEI per µg DNA and 0.9 µg of a luciferase reporter plasmid under the control of the c-Myc promoter with four wildtype c-Myc binding sites (WT MBS1-4) or mutated c-Myc binding sites (mut MBS1-4) 55 , 0.9 µg of control or shRNA plasmid and 0.2 µg of pCDNA3-LacZ plasmid 56 . The medium was replaced the next day and two days after transfection, luciferase activity was measured using the Luciferase Assay System (Promega). Values were normalized for β-Galactosidase LacZ activity as a transfection efficiency control.
In vitro protease assay U2OS cells stably expressing His-SUMO2 were treated with MG132 and a His-SUMO2 purification was performed as described above. In a total volume of 30 µl, 0.5 µl of 50 µM SENP2 and/or USP2 catalytic domain stock solutions (Boston Biochem) were added to the purified samples in deSUMOylation buffer (1.75 M urea, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 and 10 mM Tris pH 7.0). Samples were incubated for 3 hours at room temperature, before the SENP2 or USP2 catalytic domains were added again and incubated for another 3 hours. Samples were analyzed by SDS-PAGE and immunoblotted using antibodies against c-Myc, phospho-c-Myc, SUMO2/3 and ubiquitin. Lysates of cells expressing His-tagged ubiquitin in combination with Flag-tagged SUMO2 contained all modified and unmodified proteins. First, a His-ubiquitin pulldown was performed to enrich for ubiquitylated proteins. Subsequently, the ubiquitin and SUMO2 comodified proteins were selected from this sample via Flag-SUMO2 immunoprecipitation (IP). S: SUMOylation, Ub: ubiquitylation and P: phosphorylation. (B) U2OS cells stable expressing His-ubiquitin and Flag-SUMO2 were treated for 6 hours with DMSO or the proteasome inhibitor MG132. Input samples were taken and a double purification was performed as described above. Input samples, single and double purified samples were separated by SDS-PAGE, transferred onto a membrane and incubated with antibodies to detect c-Myc or the Flag-tag. Equal amounts of starting material were used for the single purification sample and for the double purified sample, enabling a comparison of these samples. Figure S2 . PIAS1 overexpression enhances endogenous c-Myc SUMOylation. U2OS cells stably expressing His-SUMO2 were transfected with a control plasmid or Flag-tagged PIAS constructs. Two days after transfection these cells were treated for 6 hours with the proteasome inhibitor MG132, lysed and a His-SUMO2 pulldown was performed. Input and pulldown samples were separated by SDS-PAGE, transferred onto a membrane and incubated with antibodies to detect c-Myc, SUMO2/3 and the Flag-tag.
